Partners Group Listed Investments SICAV - Listed Private Equity - GBP (I - Dist.)

Monthly report as of 30 September 2018

Fund objectives

The Partners Group Listed Investments SICAV – Listed Private Equity fund provides efficient access to the asset class private equity overcoming the normally associated hurdle of illiquidity. The Fund invests in companies which mainly focus on private equity investments and are listed on major stock exchanges. Out of an investment universe of over 200 companies world wide, the Fund actively screens a target list of around 100 companies, which fit the minimum criteria.

Fund facts	
Inception date	17/05/2010
Asset manager	Partners Group AG
Fund domicile	Luxembourg
Fund currency	EUR
Share class currency	GBP
Minimum initial investment amount	GBP 1m
Close of financial year	31 December
Total net assets	GBP 181.1m
Management fee in % p.a.	1.15
Distributions	Distributing
Last distribution	28/08/2018
Distribution value	GBP 4.06
Valor no.	10137954
ISIN	LU0424511698
Bloomberg ticker	PGLLPEG LX
WKN	AORMTL

Price development	
Price per unit 28/09/2018	GBP 297.27
Price per unit 31/08/2018	GBP 294.02
Change (total return)	1.1%
Investment level	99%


Top 5 holdings	
	in % of NAV
Blackstone Group	9.16
Partners Group Holding AG	9.05
KKR & Co.	7.30
Wendel	6.12
Ares Capital	5.59
Total	37.22

Monthly comment

Partners Group Listed Investments SICAV – Listed Private Equity finished the third quarter successfully and recorded a significant NAV-gain since the beginning of the year. In September, the value of the fund increased further and outperformed the broader equity market. All market segments contributed positively to the monthly performance, whereby the US alternative asset managers achieved the largest increase in value.

For example, the US alternative asset manager Ares Management performed particularly well in the reporting month. The market reacted positively to the announcement that the major shareholder up to this point, Abu Dhabi Investment Authority, had completed the sale of its entire stake. Also the US alternative asset manager Blackstone convinced investors in September as well. The management confirmed at its investor day the outlook to increase its assets under management from USD 439 billion to USD 1 trillion over the next eight years.

Furthermore, the shares of the Switzerland based investment firm HBM Healthcare achieved the largest value gain. The portfolio company Y-mAbs Therapeutics made its IPO on the New York stock exchange. The share price of the oncology product provider increased by 50% on the first trading day. As a result of this, the NAV of HBM Healthcare rose by 2.7%.



Performance in %	1 month %	YTD %	1 year %	3 years %	5 years %	since inception %
Fund*	1.1	10.1	13.2	91.2	112.8	222.3
MSCI World**	-0.2	8.3	14.8	73.2	90.8	157.1

Volatility in % (annualized)	1 year	3 years	5 years	since inception
Fund*	10.2	11.9	11.6	14.5
MSCI World**	10.7	11.6	11.6	14.8

^{*}Total return **MSCI World (NR) (NAV T-1)



Note: This share class is approved for distribution in Ireland, Switzerland, Austria, Denmark, Finland, France, Germany, Luxembourg, Netherlands, Norway, Singapore, Spain, Sweden, United Kingdom. In all other countries, the Fund may not be publicly distributed.



Partners Group Listed Investments SICAV - Listed Private Equity - GBP (I - Dist.)

Monthly report as of 30 September 2018

Definitions

This monthly report is produced based on information available on the last working day of the month.

Listed Private Equity A 'Listed Private Equity' company is listed on a stock exchange and has the purpose of investing in private equity assets.

Total returnTotal return is calculated according the standard BVI-method of the Bundesverband Investment and Asset Management.

Investment universe Public partnerships, fund of funds, private equity houses, mixed investment companies

Financing stages

Venture capital Financing for companies typically in their build-up phase. Seed stage describes the period where product feasibility is

confirmed; Early stage involves the identification of the position in the market, the establishment of production lines and the development of marketing channels; Later stage portrays the subsequent rapid expansion phase of a young company.

BuyoutAcquisition of a controlling stake in a company, typically with financial or managerial reorganization needs. Small/mid/large

size buyout refers to the enterprise value of the acquired company. Whereas the bandwidths for Europe are set at <EUR 100m/EUR 100m-EUR 400m/>EUR 400m, US bandwidths are at <USD 300m/USD 300m-USD 1bn/>USD 1bn for

small/mid/large size buyout respectively.

Private debt Financing solutions for enterprises with no access to capital markets. Includes, among others, investments in senior

secured and subordinated debt as well as preferred equity.

Contact details

Asset manager:

Partners Group AG Zugerstrasse 57 6341 Baar-Zug Switzerland

T +41 (0)41 784 60 00 www.pgliquids.com

Investor relations: Partners Group AG

Philipp Kuny Zugerstrasse 57

6341 Baar-Zug / Schweiz

T +41 (0)41 784 68 14

listedinvestments@partnersgroup.com

The relevant articles of incorporation, prospectus, key investor information document (KIID) and the latest annual/semi-annual reports are available free of charge from the fund's representative in Switzerland, ACOLIN Fund Services AG, Affolternstrasse 56, CH-8050 Zürich. The paying agent in Switzerland is: Credit Suisse (Switzerland) AG, Paradeplatz 8, CH-8001 Zürich.

 $Partners\ Group\ Listed\ Investments\ SICAV,\ 5,\ rue\ Jean\ Monnet,\ L-2180\ Luxembourg,\ Grand\ Duchy\ of\ Luxembourg,\ R.C.S.\ Luxembourg\ B\ 143187$

This document is not intended to be an investment advertisement or sales instrument; it constitutes neither an offer nor an attempt to solicit offers for the product described herein. The sole basis for the purchase of shares are the sales documents (the current sales prospectus incl. articles of association and the annual- and semi-annual reports). This report was prepared using financial information contained in the company's books and records as of the reporting date. This information is believed to be accurate but has not been audited by any third party. This report describes past performance, which may not be indicative of future results. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming units. The company does not accept any liability for actions taken on the basis of the information provided. Please see the current full sales prospectus for information on opportunities and risks.

